New Alzheimer's drug targeting A beta BAN2401, starts Phase III clinical study
-
Last Update: 2020-07-16
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Biogen and Eisai !---- announced the start of Phase 3 clinical studies on BAN2401 for the treatment of Alzheimer's disease (AD)BAN2401 is an antibody that is resistant to amyloid (A-beta) and is designed to selectively neutralise and remove toxic A-beta proteins, which are considered to be one of the factors that cause ADahead 3-45 program is divided into Two Trials, A3 and A45, to assess ban2401's potential to reduce harmful A-beta accumulation and cognitive decline in the brainA3 trial sits participants with moderate a-beta levels in the brain who are at higher risk of a beta build-up, and the A45 trial will recruit participants with elevated amyloid levels in the brainThePhase 3 clinical trial followed a promising outcome in Phase 2 clinical trials, which showed that high doses of BAN2401 significantly slowed cognitive decline and reduced A-beta deposition in the brain at the 18-month pointhowever, patients taking low-dose BAN2401 appeared to have a faster cognitive decline than those who took a placeboAlthough partner companies stress that the phenomenon may be due to an imbalance caused by the rapid development of genetically sensitive patients, the lack of a clear dose response at the clinical endpoint casts doubt on the efficacy of the drug
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
